"The next step is to finalize data processing and analysis" says Professor Mats Jontell, co-founder of Mucocort.Mucocort AB today announces that patient enrolment in the clinical study RAS01-M045A has been completed. This marks an important milestone in the development of M045A, a locally applied treatment being evaluated for recurrent aphthous ulcers in the oral cavity.
RAS01-M045A is a clinical study evaluating M045A, a mucoadhesive, biodegradable patch applied directly to aphthous ulcers. The study is designed to evaluate the clinical performance and safety of the product, with a particular focus on pain immediately after application of the patch and over the following hours.
With planned patient enrolment now complete, the study will proceed to final data processing, analysis, and scientific evaluation.
“Completion of patient enrolment represents an important milestone in the clinical development program for M045A. The next step is to finalize data processing and analysis. We look forward to presenting the results once this work is complete,” says Professor Mats Jontell, co-founder of Mucocort and Professor of Oral Medicine and Oral Pathology.
The compilation and scientific evaluation of the study data are now underway. Mucocort aims to present overall results from the study in late 2026 or early 2027, followed by publication of the study data in a peer-reviewed scientific journal.
The results from RAS01-M045A are expected to play an important role in the continued development of M045A and provide clinical evidence to support upcoming regulatory activities and further product development.
About RAS01-M045A
* RAS01-M045A is a clinical study of M045A in patients with recurrent aphthous ulcers in the oral cavity. Recurrent aphthous ulcers, commonly known as canker sores, are a common condition affecting the oral mucosa and can cause significant pain and discomfort.
* M045A is a mucoadhesive, biodegradable patch that is applied directly to aphthous ulcers and is being evaluated as a locally applied treatment.
* The purpose of the study is to evaluate the clinical performance and safety of M045A, with a particular focus on pain following application.
* The study is being conducted in Sweden, and planned patient enrolment has now been completed. The study will proceed to data processing, analysis, and scientific evaluation ahead of the presentation of the results.
About Mucocort AB
Mucocort AB is a Swedish life sciences company developing innovative solutions for the local treatment of conditions affecting the oral mucosa. The company’s lead development project, M045A, is being clinically evaluated for the treatment of recurrent aphthous ulcers.
For further information, contact:
Jean Lycke
Project Manager, Mucocort AB
Email: jl@emerentiagruppen.com
Tel: +46(0)70 277 15 11
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.
Powered by Notified